A multicenter proof-of-concept study on deep learning-based intraoperative discrimination of primary central nervous system lymphoma.
Xin-Ke ZhangZihan ZhaoRuixuan WangHaohua ChenXueyi ZhengLili LiuLilong LanPeng LiShuyang WuQinghua CaoRongzhen LuoWan-Ming HuShanshan LyuZhengyu ZhangDan XieYa-Ping YeYu WangMu-Yan CaiPublished in: Nature communications (2024)
Accurate intraoperative differentiation of primary central nervous system lymphoma (PCNSL) remains pivotal in guiding neurosurgical decisions. However, distinguishing PCNSL from other lesions, notably glioma, through frozen sections challenges pathologists. Here we sought to develop and validate a deep learning model capable of precisely distinguishing PCNSL from non-PCNSL lesions, especially glioma, using hematoxylin and eosin (H&E)-stained frozen whole-slide images. Also, we compared its performance against pathologists of varying expertise. Additionally, a human-machine fusion approach integrated both model and pathologic diagnostics. In external cohorts, LGNet achieved AUROCs of 0.965 and 0.972 in distinguishing PCNSL from glioma and AUROCs of 0.981 and 0.993 in differentiating PCNSL from non-PCNSL lesions. Outperforming several pathologists, LGNet significantly improved diagnostic performance, further augmented to some extent by fusion approach. LGNet's proficiency in frozen section analysis and its synergy with pathologists indicate its valuable role in intraoperative diagnosis, particularly in discriminating PCNSL from glioma, alongside other lesions.
Keyphrases
- deep learning
- convolutional neural network
- diffuse large b cell lymphoma
- artificial intelligence
- machine learning
- endothelial cells
- magnetic resonance imaging
- high resolution
- clinical trial
- neoadjuvant chemotherapy
- cross sectional
- cerebrospinal fluid
- lymph node
- computed tomography
- optical coherence tomography
- double blind
- induced pluripotent stem cells
- contrast enhanced